B. Riley Weighs in on Immunic’s Q1 Earnings (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at B. Riley issued their Q1 2026 EPS estimates for Immunic in a research note issued on Tuesday, November 25th. B. Riley analyst W. Wood forecasts that the company will earn ($0.10) per share for the quarter. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.10) EPS.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05.

IMUX has been the subject of a number of other research reports. LADENBURG THALM/SH SH raised Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. HC Wainwright dropped their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 14th. D. Boral Capital decreased their target price on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Immunic presently has an average rating of “Buy” and an average target price of $7.40.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $0.70 on Wednesday. Immunic has a 1 year low of $0.56 and a 1 year high of $1.42. The company has a market cap of $84.32 million, a P/E ratio of -0.75 and a beta of 1.53. The stock’s fifty day moving average price is $0.81 and its 200-day moving average price is $0.84.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Qube Research & Technologies Ltd bought a new stake in Immunic during the 3rd quarter worth approximately $29,000. Two Sigma Investments LP purchased a new stake in shares of Immunic in the third quarter worth $52,000. HB Wealth Management LLC bought a new stake in shares of Immunic during the 3rd quarter valued at $81,000. Virtu Financial LLC purchased a new position in shares of Immunic during the 3rd quarter valued at $99,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Immunic during the 3rd quarter valued at $170,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.